-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Dolphin Congratulates Shore Fire Media and Its Clients on 20 GRAMMY(R) Nominations, Including 10 Best Album Nods Across Diverse Genres
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Dermata Announces U.S. Trademark Registration for TOME(R)
-
Olenox October Bitcoin Production Climbs to Three-Month High as Uptime and Hashrate Advance
-
5E Advanced Materials Highlights Commercial Momentum in First Month as an Operating Borates Producer
-
Trout CPA Expands Partner Leadership with Michael Carr and Dan Lerew
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Jumia Reports Third Quarter 2026 Results
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
What to Do When Two Households Become One
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
TrizCom PR Wins Fourth PRSA Dallas Best of Show Award; Founder Jo Trizila Receives Norm Teich Award
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
First Covid vaccine side-effect claims land in German courts
Vaccine-maker BioNTech faced Monday its first legal claim in its home country of Germany over adverse effects allegedly suffered by some users of its Covid vaccines, more than two years after one of the world's fastest and most extensive inoculation campaigns.
In the face of the deadly pandemic that emerged in early 2020, which prompted border closures and lockdowns that trapped millions of people in their homes, the arrival of Covid vaccines had been widely hailed as a life-saver.
But the jabs, which had been developed at breakneck speed and granted early approval for usage, are now the focus of legal procedures in several countries including France and Britain where plaintiffs argue that the vaccines harmed their health.
In Germany, a court in Hamburg was prepared to hear a case from Monday against BioNTech, which, together with US giant Pfizer, produced the first mRNA vaccine Comirnaty.
The hearing was delayed however after the claimant's lawyers put in a last-minute challenge of the judge's impartiality, and asking instead for a panel of judges to rule on the case.
In her claim, the plaintiff reported suffering effects including "pain in the upper body, swelling of the extremities, exhaustion, fatigue and sleeping disorders" after receiving the vaccine, the court said.
She is seeking 150,000 euros ($162,000) in damages and recognition that the "defendant is bound to provide material damages", the court added.
Her lawyer Thomas Ulbrich, who is also representing another 250 people in similar cases, said his clients were "all healthy" before suffering from symptoms, allegedly following their jabs.
He believes that the medical files he has on hand offer a link between the vaccines and the symptoms experienced by his clients.
- 'Rocky and long road' -
BioNTech's mRNA vaccine, a scientific breakthrough, had been granted conditional marketing authorisation as early as December 21, 2020, by the EU regulatory authority EMA.
Similar authorisation for Moderna, another mRNA vaccine maker, swiftly followed.
With fears of catching the disease running high, the vaccines were pre-ordered by governments even during their development phases, and deployment swiftly followed once regulatory authorities gave their approval.
But the new generation of inoculations also sparked a wave of vaccine sceptics questioning the safety of the jabs.
Out of 192 million jabs given in Germany, the country's medicines regulator, the Paul Ehrlich Institute, said 338,857 suspected cases of side effects were reported, including 54,879 severe reactions.
Among the worst cases, "the symptoms are very different, they vary from stroke to thrombosis to cardiac diseases", said another German lawyer, Joachim Caesar-Preller, who represents 140 clients making similar claims.
He is seeking up to one million euros in damages per case -- plus interest -- but concedes that a "rocky and long road" lies ahead in the legal battles.
- 'Not an isolated case' -
A key point for the courts is whether the side effects of the medication, when used correctly, surpass "a justifiable level according to the findings of medical science".
In other words, the effects have to be sufficiently serious to be taken into account, said Anatol Dutta, a professor at Munich University.
A claimant identified only as Kathrin K., 45, believes her symptoms are severe enough.
She said she lost a lot of weight after taking the vaccine and had to undergo several intestinal operations.
"I hate it when people tell me that I'm an isolated case," she said. "I'm not."
To address the question of causality, the courts would likely have to obtain expert advice.
Besides the legal avenue, claimants can also turn to the state for compensation for the loss of income.
More than 8,000 such applications had been made as of April, and so far about five percent have been successful, according to German media.
BioNTech told AFP that the number of liability claims made to the company is very small when compared to the number of doses it has delivered worldwide, and that each claim had to be examined individually.
"Justified liability claims would of course be met by BioNTech," it said, adding however that "no causal relationship between (the) health impairments presented and vaccination with Comirnaty has been proven" in the cases it had reviewed so far.
Another lawyer, Anja Dornhoff, advises her clients to establish a chronology and to get medical practitioners to document the development of their symptoms.
"I hope that people with post-vaccination syndromes can be taken seriously," she said.
O.Brown--AT